CA180-357 = Decitabine + Dasatinib for Blast Phase CML

Study title

CA180-357 = Decitabine + Dasatinib for Blast Phase CML [USA]

Scientific title

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) [USA]
( No. NCT01498445)

Type of study

Treatment of advanced disease
In a single country

Current status

The study was terminated due to slow enrollment.

What is the purpose of the study

Patients with accelerated or blast phase CML are treated with a combination of decitabine and dasatinib. They will take dasatinib by mouth once a day and they will receive decitabine by vein for up to 10 days in each 28-day cycle.

Key inclusion criteria

This study includes patients age 18 years of age or older with chronic myelogenous leukemia in accelerated phase (CML-AP) or in blast phase (CML-BP). Patients may be previously treated or previously untreated.

Key exclusion criteria

Where can I find additional information

Study description in the US register, a service of the U. S. National Institutes of Health

Study sponsor

MD Anderson Cancer Center

Scientific lead / contact

Jorge Cortes

Principal investigator

Jorge Cortes

Study centers / principal investigators

United States

MD Anderson Cancer Center
University of Texas
Houston, Texas